Mollugin 大叶茜草素|cas:55481-88-4|西域试剂

Mollugin 大叶茜草素,99.48%

产品编号：Bellancom-N0316| CAS NO：55481-88-4| 分子式：C₁₇H₁₆O₄| 分子量：284.31

Mollugin 是 Rubia cordifolia L. 中主要的一种生物活性成分。Mollugin 通过抑制 TNF-α 诱导的 NF-κB 激活起抗癌疗效。Mollugin 能通过 p38-Smad 信号通路增强 BMP-2 的成骨作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-N0316	￥500.00	杭州北京（现货）
Bellancom-N0316	￥900.00	杭州北京（现货）
Bellancom-N0316	￥1500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mollugin 大叶茜草素

产品介绍

Mollugin 是一种口服有效的 NF-κB 抑制剂。Mollugin 诱导 HepG2 细胞 S 期阻滞，增加细胞内活性氧 (ROS) 水平。Mollugin 诱导 HepG2 细胞 DNA 损伤，并增加 p-H2AX 的表达。Mollugin 通过抑制 TNF-α 诱导的 NF-κB 活化而具有抗癌作用。Mollugin 通过 p38-Smad 信号通路增强 BMP-2 (骨形态发生蛋白 2) 的成骨作用。

生物活性

Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway.

体外研究

Mollugin (0-80 μM, 24 h) inhibits the expression of an NF-κB reporter gene induced by TNF-α in a dose-dependent manner.
Mollugin (0-80 μM, 12 h) inhibits the proliferation of HeLa cells.
Mollugin (0-80 μM, 12 h) inhibits TNF-α-induced phosphorylation and nuclear translocation of p65, phosphorylation and degradation of IκBα, and IKK phosphorylation, and inhibits the TNF-α-induced mRNA expression of Cyclin D1, c-Myc, and VEGF.
Mollugin (0-80 μM, 12 h) enhances TNF-α-induced apoptosis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HeLa, Hep3B, and HEK293 cells
Concentration:	0, 10, 20, 40, and 80 μM
Incubation Time:	24 h
Result:	Significantly inhibited NF-κB reporter gene expression in a dose-dependent manner, did not display significant cellular toxicity in HeLa, Hep3B, and HEK293 cells.

Cell Proliferation Assay

Cell Line:	HeLa cells
Concentration:	0, 20, 40, and 80 μM
Incubation Time:	12 h
Result:	Inhibited the proliferation of HeLa cells.

Apoptosis Analysis

Cell Line:	HeLa cells
Concentration:	0, 10, 20, 40, and 80 μM
Incubation Time:	12 h
Result:	Slightly affected the caspase-3 activation, potentiated the effect of TNF-α-induced PARP cleavage, and enhanced the apoptotic effects of TNF-α.

Western Blot Analysis

Cell Line:	HeLa cells
Concentration:	0, 10, 20, 40, and 80 μM
Incubation Time:	12 h
Result:	Significantly inhibited the TNF-α-induced p65 phosphorylation and block TNF-α-induced nuclear translocation of p65 in a dose-dependent manner, completely inhibited degradation of IκBα at 80 μM, and abolished the TNF-α-induced IKK phosphorylation at 80 μM. Inhibited the TNF-α-induced mRNA expression of Cyclin D1, c-Myc, and VEGF at 80 μM.

体内研究
(In Vivo)

Mollugin (0-75 mg/kg, Orally, three times per week for 36 days) inhibits growth of HeLa cells in a xenograft tumor model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c female athymic nude mice (six-week-old, subcutaneously injected with 0.2 mL HeLa cells)
Dosage:	0, 25 and 75 mg/kg
Administration:	Orally, three times per week for 36 days
Result:	Suppressed tumor growth, whereas the body weight did not change. Significantly reduced the protein expression of p-p65 and COX-2 in the tumors.

体内研究

Mollugin (0-75 mg/kg, Orally, three times per week for 36 days) inhibits growth of HeLa cells in a xenograft tumor model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c female athymic nude mice (six-week-old, subcutaneously injected with 0.2 mL HeLa cells)
Dosage:	0, 25 and 75 mg/kg
Administration:	Orally, three times per week for 36 days
Result:	Suppressed tumor growth, whereas the body weight did not change. Significantly reduced the protein expression of p-p65 and COX-2 in the tumors.

体内研究

Mollugin (0-75 mg/kg, Orally, three times per week for 36 days) inhibits growth of HeLa cells in a xenograft tumor model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c female athymic nude mice (six-week-old, subcutaneously injected with 0.2 mL HeLa cells)
Dosage:	0, 25 and 75 mg/kg
Administration:	Orally, three times per week for 36 days
Result:	Suppressed tumor growth, whereas the body weight did not change. Significantly reduced the protein expression of p-p65 and COX-2 in the tumors.

性状

Solid

溶解性数据

In Vitro:

DMSO : 33.33 mg/mL (117.23 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5173 mL	17.5864 mL	35.1729 mL
5 mM	0.7035 mL	3.5173 mL	7.0346 mL
10 mM	0.3517 mL	1.7586 mL	3.5173 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.79 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.79 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献

. Wang Z, et al. Mollugin Has an Anti-Cancer Therapeutic Effect by Inhibiting TNF-α-Induced NF-κB Activation. Int J Mol Sci. 2017 Jul 26;18(8). [Content Brief]

. Moon SH, et al. Mollugin enhances the osteogenic action of BMP-2 via the p38-Smad signaling pathway. Arch Pharm Res. 2017 Nov;40(11):1328-1335. [Content Brief]

. Ke XG, Xiong YY, Yu B, et al. Mollugin induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in hepatoma cells. Chem Biol Interact. 2022;353:109805. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

安全声明 (欧洲)	24/25
危险品运输编码	NONH for all modes of transport
海关编码	29329990

1. 物质的识别

产品名：	Rubimaillin
CAS号：	55481-88-4
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Rubimaillin
分子式：	C17H16O4
分子量：	284.31

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	4°C, protect from light, dry, sealed

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。